Bold Therapeutics: Funding, Investors & Team (Sep 2026)
Bold Therapeutics is a clinical-stage biotech company that develops and commercializes an anti-resistance therapeutic. Its product BOLD-100, a ruthenium-based small molecule therapeutic, improves the activity of a wide range of other anti-cancer therapies by disabling a critical and previously untargeted cancer resistance, survival, and proliferation pathway. Bold Therapeutics is focusing its clinical development efforts on some of the most challenging cancer indications where existing therapies are largely ineffective, resulting in a significant unmet medical need.
Bold Therapeutics has raised $800k across 1 funding round on record, the most recent an undisclosed round of $800k announced in Jun 2021.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Bold Therapeutics Company Profile and Key Stats
Latest funding round on record: Jun 2021.
Bold Therapeutics Funding Rounds
Bold Therapeutics Founders and Leadership Team
Contact details for the Bold Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Bold Therapeutics Funding Compared to Other Biotechnology Startups
Bold Therapeutics' latest round of $800k is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Bold Therapeutics in Biotechnology and Vancouver
Companies Similar to Bold Therapeutics
Medicenna is a clinical-stage immunotherapy company focused on oncology and the development and…
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective…
Hemostemix Inc. is a Canadian biotechnology company that specializes in creating blood-derived cell therapies…
Avicanna is an organization in the biopharmaceutical sector that concentrates on enhancing medical cannabis…
Edesa Biotech is a privately-held company in the clinical stage that specializes in creating therapies for…
ME Therapeutics is a biotech company that specializes in finding and creating drugs for immuno-oncology that…
Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and…
Medicus Pharma is a biotechnology research company that fast-tracks the progress of life sciences and…
ProteinQure is a biotechnology company specializing in creating innovative peptides for various medical…
Anodyne's mission is to create critical chemicals sustainably. Anodyne's approach takes advantage of nature's…
NervGen Pharma is a medicine company dedicated to creating solutions for the treatment of nerve damage and…
ZYUS is a biopharmaceutical company focused on providing patients with cannabinoids and other plant-based…
Bold Therapeutics Funding FAQs
What does Bold Therapeutics do?
Bold Therapeutics is a clinical-stage biotech company that develops and commercializes an anti-resistance therapeutic. Its product BOLD-100, a ruthenium-based small molecule therapeutic, improves the activity of a wide range of other anti-cancer therapies by disabling a critical and previously untargeted cancer resistance, survival, and proliferation pathway. Bold Therapeutics is focusing its clinical development efforts on some of the most challenging cancer indications where existing therapies are largely ineffective, resulting in a significant unmet medical need.
How much funding has Bold Therapeutics raised?
Bold Therapeutics has raised $800k across 1 round on record. The most recent is an undisclosed round of $800k announced in Jun 2021.
When did Bold Therapeutics last raise funding?
Bold Therapeutics' most recent funding round on record is an undisclosed round of $800k, announced in Jun 2021.
Who is the CEO of Bold Therapeutics?
Russell McAllister is listed as CEO at Bold Therapeutics.
Where is Bold Therapeutics headquartered?
Bold Therapeutics is based in Vancouver, British Columbia, Canada.
How many employees does Bold Therapeutics have?
Bold Therapeutics is in the 11-50 employee band.
How does Bold Therapeutics' funding compare to other Biotechnology startups?
Bold Therapeutics' latest round of $800k is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's Bold Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Bold Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.